MSLNL Inhibitors
MSLNL inhibitors, also known as MSLNL (Methylated-seryl-leucyl-norleucinal) protease inhibitors, constitute a distinct chemical class within the realm of bioactive compounds. These inhibitors are specifically designed to target and modulate the activity of proteolytic enzymes known as MSLNL proteases. MSLNL proteases are a family of enzymes responsible for regulating the degradation of specific protein substrates within cells, playing crucial roles in cellular homeostasis and various physiological processes. MSLNL inhibitors, through their unique chemical structure and mechanism of action, interact with and influence the activity of these proteases, thus offering insights into the intricate world of proteolysis and protein turnover.
At a molecular level, MSLNL inhibitors are characterized by their ability to bind to the active site of MSLNL proteases, forming reversible complexes that interfere with the normal proteolytic activity of these enzymes. The chemical structure of MSLNL inhibitors typically consists of specific functional groups that interact with key amino acid residues within the protease's active site, effectively blocking its substrate-binding and cleavage capabilities. This interference ultimately results in the modulation of intracellular protein degradation pathways, leading to downstream effects on cellular processes. The development and study of MSLNL inhibitors contribute to a deeper understanding of protease-mediated protein turnover and may have implications in various fields of biology and molecular biology, such as elucidating the roles of proteases in cellular signaling and protein quality control.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits the activity of BCR-ABL kinase, a fusion protein responsible for chronic myeloid leukemia, by binding to its ATP-binding site, blocking downstream signaling and cell proliferation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor that blocks the autophosphorylation of EGFR, inhibiting downstream signaling pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple kinases, including RAF kinases and VEGFR, inhibiting angiogenesis and cell proliferation in cancers like hepatocellular carcinoma and renal cell carcinoma. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a JAK1 and JAK2 inhibitor that reduces inflammation and cell proliferation by blocking the JAK-STAT signaling pathway and is used for myelofibrosis and polycythemia vera. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib inhibits EGFR tyrosine kinase activity, blocking the growth and spread of cancer cells in EGFR-mutated non-small cell lung cancer (NSCLC). | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 selectively inhibits BCL-2, promoting apoptosis in BCL-2 dependent cancer cells, such as those in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
Olaparib is a PARP inhibitor that disrupts DNA repair in BRCA-mutated cancer cells, leading to synthetic lethality, making it effective against ovarian and breast cancers with BRCA mutations. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib targets BTK in B-cell receptor signaling, inhibiting B-cell survival and proliferation, and is used for B-cell malignancies like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual HER2 and EGFR inhibitor that blocks tyrosine kinase activity, hindering the growth of HER2-positive breast cancer cells by disrupting HER2 signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a multi-kinase inhibitor that targets SRC family kinases and BCR-ABL, inhibiting cell growth in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). | ||||||